Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection

Trial Profile

A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INO 8000 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 14 Sep 2018 New trial record
    • 04 Sep 2018 According to an Inovio Pharmaceuticals media release, first patient has been doses in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top